Strand was founded by biological  engineers working together at the Massachusetts Institute of Technology (MIT). Building on the  idea of creating smart therapies  capable of making sophisticated decisions, they sought to apply this  concept to the emerging field  of  mRNA therapeutics. This area was  previously untapped by traditional  synthetic biology, leading us to  build our very own mRNA programming language, creating  the world’s first platform for mRNA  smart therapies.  

Strand’s mRNA programming  technology promises to make  mRNA therapies safer and more  effective by programming the  location, timing, and intensity of  therapeutic protein expression inside a patient’s body via mRNA-encoded logic circuits. These circuits have the ability to implement cell-type specific expressions by sensing and classifying the unique mRNA expression signatures of cells and control the dosage of protein expression through responses to exogenously administered small molecules.